Drug intelligence / Profile preview

eP53

Development stage: Preclinical
Lead developer: PEEL Therapeutics
Modality: Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

**eP53** is the elephant TP53 protein, leveraging elephants' natural cancer resistance due to multiple TP53 gene copies that enhance p53-mediated apoptosis. Delivered via liposomal nanoparticles by PEEL Therapeutics, eP53 induces rapid and robust cell death in human cancer cells, particularly osteosarcoma, by restoring or enhancing p53 function and triggering apoptosis even in p53-mutant contexts. Developed from research by Dr. Joshua Schiffman and Dr. Avi Schroeder, it targets pediatric bone tumors lacking new therapies in over 40 years, with preclinical efficacy shown in vitro and in patient-derived xenograft models.

Other names: elephant p53

Targets

BCL2L1 (B-cell lymphoma-extra large protein)

Beyond the preview

Go deeper on eP53.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eP53.

Explore the full profile